Company intelligence / Profile preview

Geneticure

Rochester, Minnesota, United Statesgeneticure.com ↗

Ownership: Private
Development stage: Commercial

Overview

Geneticure has developed a patented pharmacogenomic test that uses a patient’s DNA to recommend personalized hypertension treatment. Clinical trials have shown that their approach leads to a 36% greater reduction in blood pressure compared to standard of care, with outcomes equivalent to a 40% risk reduction in major cardiovascular events and at 47% lower cost than standard approaches. The technology reduces trial-and-error prescribing and improves patient outcomes.

Therapeutic areas: OtherCardiovascular
Modalities: Diagnostic testPharmacogenomic panel
Industry: Molecular Diagnostics

Partnerships

Mayo Clinic

Beyond the preview

Go deeper on Geneticure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Geneticure.

Explore the full profile